Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Stefano Bramante, Gabriele Di Salvo, Giuseppe Maina & Gianluca Rosso. (2023) Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs. Neuropsychiatric Disease and Treatment 19, pages 519-530.
Read now
Read now
Maryia Zhdanava, H Lynn Starr, Patrick Lefebvre, Todor I Totev, Aditi Shah, Kristy Sheng & Dominic Pilon. (2022) Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey. Neuropsychiatric Disease and Treatment 18, pages 1479-1493.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Articles from other publishers (9)
Qian Li, Xin Li, Chong Ye, Miaomiao Jia & Tianmei Si. (2024) Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review. BMC Psychiatry 24:1.
Crossref
Crossref
Rachel Hird, Rajiv Radhakrishnan & Jack Tsai. (2024) A systematic review of approaches to improve medication adherence in homeless adults with psychiatric disorders. Frontiers in Psychiatry 14.
Crossref
Crossref
Qian Li, Xin Li, Chong Ye, Miaomiao Jia & Tianmei Si. (2023) Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis. CNS Drugs 37:8, pages 695-713.
Crossref
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Crossref
Charmi Patel, Ahong Huang, Li Wang, Yoshita Paliwal & Kruti Joshi. (2022) Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in Therapy 39:3, pages 1199-1214.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Rohan Mahabaleshwarkar, Dee Lin, Jesse Fishman, Todd Blair, Timothy Hetherington, Pooja Palmer, Charmi Patel, Carmela Benson, Kruti Joshi, Constance Krull & Oleg V. Tcheremissine. (2021) The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study. Advances in Therapy 38:4, pages 1958-1974.
Crossref
Crossref
Maryia Zhdanava, Dee Lin, Marie-Hélène Lafeuille, Isabelle Ghelerter, Laura Morrison, Patrick Lefebvre & Kruti Joshi. (2021) Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse. Clinical Therapeutics 43:3, pages 535-548.
Crossref
Crossref